Search Advanced

Mathematical Biosciences and Engineering

2015, Volume 12, Issue 6: 1203-1217. doi: 10.3934/mbe.2015.12.1203
Previous Article Next Article

The role of the cytokines IL-27 and IL-35 in cancer

  • 1.
    Mathematical Biosciences Institute, The Ohio State University, Columbus, OH 43210
  • 2.
    Mathematical Biosciences Institute, The Ohio State University, Columbus, OH
  • Published: 01 August 2015

  • MSC : 92C50, 92C37, 92C45, 35Q92, 35Q68.

  • The cancer-immune interaction is a fast growing field of research in biology, where the goal is to harness the immune system to fight cancer more effectively. In the present paper we review recent work of the interaction between T cells and cancer. CD8$^+$ T cells are activated by IL-27 cytokine and they kill tumor cells. Regulatory T cells produce IL-35 which promotes cancer cells by enhancing angiogenesis, and inhibit CD8$^+$ T cells via TGF-$\beta$ production. Hence injections of IL-27 and anti-IL-35 are both potentially anti-tumor drugs.The models presented here are based on experimental mouse experiments, and their simulations agree with these experiments. The models are used to suggest effective schedules for drug treatment.

    Citation: Avner Friedman, Kang-Ling Liao. The role of the cytokines IL-27 and IL-35 in cancer[J]. Mathematical Biosciences and Engineering, 2015, 12(6): 1203-1217. doi: 10.3934/mbe.2015.12.1203

    Related Papers:

  • The cancer-immune interaction is a fast growing field of research in biology, where the goal is to harness the immune system to fight cancer more effectively. In the present paper we review recent work of the interaction between T cells and cancer. CD8$^+$ T cells are activated by IL-27 cytokine and they kill tumor cells. Regulatory T cells produce IL-35 which promotes cancer cells by enhancing angiogenesis, and inhibit CD8$^+$ T cells via TGF-$\beta$ production. Hence injections of IL-27 and anti-IL-35 are both potentially anti-tumor drugs.The models presented here are based on experimental mouse experiments, and their simulations agree with these experiments. The models are used to suggest effective schedules for drug treatment.


    加载中
    [1] Pharmacological Reviews, 55 (2003), 241-269.
    [2] PLoS ONE, 6 (2011), e18534.
    [3] Principles of Immunopharmacology: 3rd revised and extended edition, 2011.
    [4] The Journal of Experimental Medicine, 178 (1993), 1223-1230.
    [5] Toxicologic Pathology, 27 (1999), 58-63.
    [6] J. Immunol., 186 (2011), 6661-6666.
    [7] Journal of the National Cancer Institute, 89 (1997), 1049-1058.
    [8] Bull. Math. Biol., 74 (2012), 2752-2777.
    [9] Anticancer Res., 24 (2004), 3763-3767.
    [10] Blood, 116 (2010), 3887-3898.
    [11] Nature, 450 (2007), 566-569.
    [12] Immunol. Rev., 226 (2008), 248-262.
    [13] Nature immunology, 13 (2012), 290-299.
    [14] Cytokine Growth Factor Rev., 13 (2002), 155-168.
    [15] J. Immunology, 186 (2011), 83-91.
    [16] Immunity, 21 (2004), 831-842.
    [17] Cancer Res., 69 (2009), 2133-2140.
    [18] Blood, 117 (2011), 323-331.
    [19] Blood, 98 (2001), 2143-2151.
    [20] Nat. Rev. Immunol., 12 (2012), 253-268.
    [21] J Immunol, 160 (1998), 3188-3193.
    [22] J. Immunol, 162 (1999), 1723-1729.
    [23] Cancer Res, 64 (2004), 1152-1156.
    [24] J. Immunol., 183 (2009), 6217-6226.
    [25] Nat Rev Immunol, 5 (2005), 521-531.
    [26] Modern Pathology, 24 (2011), 801-809.
    [27] J Immunol., 178 (2007), 7571-7580.
    [28] Acta Otolaryngol, 127 (2007), 532-539.
    [29] Mol. Cells, 36 (2013), 571-576.
    [30] Carcinogenesis, 34 (2012), 658-666.
    [31] PLoS ONE, 9 (2014), e91844.
    [32] PLoS ONE, 9 (2014), e110126.
    [33] European J. of Immunology, 43 (2013), 468-479.
    [34] J. Immunol., 169 (2002), 2756-2761.
    [35] Biochemical and Biophysical Research Communications, 430 (2013), 364-369.
    [36] J. Investigative Dermatology, 132 (2012), 864-871.
    [37] J. Theor. Biol., 351 (2014), 74-82.
    [38] Cancer Res., 73 (2013), 3007-3018.
    [39] Science (Wash DC), 268 (1995), p1555.
    [40] J. Biomed Biotechnol, 2010 (2010), Article ID 605483, 10 pages.
    [41] Cancer Cell, 20 (2011), 781-796.
    [42] J. Clin Invest., 117 (2007), 50-59.
    [43] BMC Immunol, 14 (2013), p30.
    [44] Hum Gene Ther, 8 (1997), 1303-1311.
    [45] 2010.
    [46] International Immunology, 21 (2012), 1105-1111.
    [47] J. Immunol., 182 (2009), 4328-4338.
    [48] J. Immunol., 173 (2004), 7170-7182.
    [49] Am. J. Pathol., 160 (2002), 1787-1798.
    [50] Int. J. Cancer, 124 (2009), 1372-1378.
    [51] Clinical Cancer Research, 13 (2007), 4345-4354.
    [52] Oncoimmunology, 2 (2013), e25409.
    [53] J. Theor. Biol., 303 (2012), 141-151.
    [54] Cancer Res., 72 (2012), 420-429.
    [55] Cancer Res., 72 (2012), 3987-3996.
    [56] Cancer Cell, 8 (2005), 369-380.
    [57] Int Immunol, 14 (2003), 1495-1504.
    [58] Nat. Rev. Immunol., 8 (2008), 523-532.
    [59] Nature immunology, 13 (2012), 722-728.
    [60] J. Experimental and Clinical Cancer Research, 30 (2011), p62.
    [61] J. Immuno., (2013).
    [62] J Immunol, 187 (2011), 266-273.
    [63] Clin. Cancer Res., 11 (2005), 8326-8331.
    [64] Clinical and Developmental immunology, 2010 (2010), Article ID 832454, 9 pages.
    [65] J. Mol Cell Biol., 5 (2013), 207-209.
    [66] 2014 Genitourinary Cancer Symposium, 2014.
    [67] Int J Clin Exp Pathol, 6 (2013), 1806-1816.
    [68] J. Immunol., 184 (2010), 2348-2354.
    [69] J. Cell Physiol., 228 (2013), 1127-1136.
  • Reader Comments
  • © 2015 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索
Mathematical Biosciences and Engineering
4.4

Metrics

Article views(3516) PDF downloads(802) Cited by(17)

Preview PDF
Download XML
Export Citation
Article outline

Other Articles By Authors

Related pages

Tools

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog